HAVCR2 and neoplasm: Several other preclinical studies on tumor-bearing mouse models have proven the efficacy of TIM-3 knockout or antibody blocking on the NK cell contribution in inhibiting sarcoma, colon carcinoma, or prostate tumor growth [50,105].